Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

CEO

Ilan Danieli

Employees

Country

United States

ISIN

US74019L5030

WKN

000A3ETCE

Listings

0 Comments

Share your thoughts

FAQ

What is Precipio stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Precipio stocks are traded under the ticker TGKP.STU.

When is the next Precipio earnings date?▼

Precipio is going to release the next earnings report on November 16, 2026.

What is Precipio revenue for the last year?▼

Precipio revenue for the last year amounts to 20.83M EUR.

What is Precipio net income for the last year?▼

TGKP.STU net income for the last year is -373,308.69 EUR.

How many employees does Precipio have?▼

As of September 04, 2026, the company has 71 employees.

In which sector is Precipio located?▼

Precipio operates in the Health & Wellness sector.

When did Precipio complete a stock split?▼

The last stock split for Precipio was on September 22, 2023 with a ratio of 1:20.

Where is Precipio headquartered?▼

Precipio is headquartered in NEW HAVEN, United States.